var data={"title":"Colchicine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Colchicine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5940?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=colchicine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Colchicine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=colchicine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Colchicine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8108144\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Colcrys;</li>\n      <li>Mitigare</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13869718\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Jamp-Colchicine;</li>\n      <li>PMS-Colchicine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154338\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antigout Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154306\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Familial Mediterranean fever (FMF):</b> Oral: Tablet (eg, Colcrys): 1.2 to 2.4 mg daily in 1 to 2 divided doses. Titration: Increase or decrease dose in 0.3 mg daily increments based on efficacy or adverse effects. Maximum dose: 2.4 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gout:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Colcrys is approved for prophylaxis and flare treatment; Mitigare is approved only for prophylaxis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Flare treatment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Initial: 1.2 mg at the first sign of flare, followed in 1 hour with a single dose of 0.6 mg (maximum: 1.8 mg within 1 hour). Patients receiving prophylaxis therapy may receive treatment dosing; wait 12 hours before resuming prophylaxis dose. <b>Note:</b> Current FDA-approved dose for gout flare is substantially lower than what has been used historically; however, doses larger than FDA-recommended dose for gout flare have not been proven more effective (EULAR [Richette 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Guideline recommendations: EULAR guidelines state that the initial colchicine dose may be given within 12 hours of flare onset (EULAR [Richette 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prophylaxis:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer&rsquo;s labeling: 0.6 mg once or twice daily; maximum: 1.2 mg daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Guideline recommendations:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">ACR guidelines: Duration of prophylaxis is 6 months or 3 months (patients without tophi) to 6 months (&ge;1 tophi) after achieving target serum uric acid levels (ACR guidelines [Khanna 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">EULAR guidelines: Duration of prophylaxis is the first 6 months of urate lowering therapy (EULAR [Richette 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Beh&ccedil;et syndrome (off-label use): </b>1 to 2 mg/day in divided doses (eg, 0.5 or 0.6 mg 3 times daily) using the lower end of the dosage range for lower body weight patients (eg, &lt;50 kg). Medication is for prolonged treatment and was studied for 2 years in a major study (Aktulga 1980; Masuda 1989; Yurdakul 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pericarditis, acute (off-label use): Note:</b> The 0.5 mg tablets are not available in the US or Canada. However, the 0.6 mg tablets are used empirically in place of 0.5 mg tablets in countries where they are not available:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Patients &gt;70 kg:</i> 0.5 mg twice daily for 3 months (Imazio 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Patients &le;70 kg or unable to tolerate higher dosing regimen:</i> 0.5 mg once daily for 3 months (Imazio 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Loading doses of colchicine used in earlier studies may not be necessary in the treatment of acute pericarditis according to newer data; lower doses are proposed to improve patient compliance and reduce adverse effects (Adler 2015; Imazio 2010b; Imazio 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Concomitant therapy:</i> Use in combination with high-dose aspirin or ibuprofen for 7 to 14 days, followed by a gradual tapering of the dose over 3 to 4 weeks (ESC [Adler 2015]). In patients with contraindications to NSAIDS/aspirin, glucocorticoid therapy has been used (eg, prednisone for 2 weeks with gradual tapering) (Imazio 2013). Concurrent gastroduodenal prophylaxis with a proton pump inhibitor has been used and is recommended (ESC [Adler 2015]; Imazio 2005a; Imazio 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pericarditis, recurrent (off-label use): Note:</b> The 0.5 mg or 1 mg tablets are not available in the US or Canada. However, the 0.6 mg tablets are used empirically in place of 0.5 mg tablets in countries where they are not available:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Regimens with loading dose:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients &ge;70 kg: 0.5 to 1 mg every 12 hours on day 1, followed by 0.25 to 0.5 mg every 12 hours for 6 months (Imazio 2005b; Imazio 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients &lt;70 kg or unable to tolerate higher dosing regimen: 0.5 mg every 12 hours on day 1, followed by 0.5 mg once daily for 6 months (Imazio 2005b; Imazio 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Regimens without loading dose:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients &gt;70 kg: 0.5 mg twice daily for 6 months (Imazio 2014a).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients &le;70 kg or unable to tolerate higher dosing regimen: 0.5 mg once daily for 6 months (Imazio 2014a).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Weight-based dosing without loading doses may improve compliance and reduce GI adverse effects according to expert opinion (ESC [Adler 2015]; Imazio 2010b; Imazio 2013). Recent data demonstrated comparable beneficial outcomes to studies that used loading doses (Imazio 2005b; Imazio 2011, Imazio 2014a).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Concomitant therapy:</i> Use in combination with high-dose aspirin, ibuprofen, or indomethacin based on initial regimen used for the acute episode and type of pericarditis (eg, idiopathic, viral, autoimmune, or post-myocardial infarction). Coadministration with corticosteroids (prednisone) is reserved for refractory cases or patients with contraindications to NSAID therapy (ESC [Adler 2015]). Proton pump inhibitors have been administered during aspirin or NSAID therapy as gastroduodenal prophylaxis (Imazio 2005b; Imazio 2011; Imazio 2014a).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postpericardiotomy syndrome (prevention) (off-label use): Note:</b> Regimens without a loading dose may improve patient compliance and reduce side effects (Imazio 2014b). The 0.5 mg or 1 mg tablets are not available in the US or Canada. However, the 0.6 mg tablets are used empirically in place of 0.5 mg tablets in countries where they are not available:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Regimens with loading dose:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients &ge;70 kg: 1 mg twice daily given on post-operative day 3, followed by 0.5 mg twice daily for 1 month (Imazio 2010a).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients &lt;70 kg or unable to tolerate higher dosing regimen: 0.5 mg twice daily given on post-operative day 3, followed by 0.5 mg once daily for 1 month (Imazio 2010a).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Regimens without loading dose:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients &ge;70 kg: 0.5 mg twice daily initiated 48 to 72 hours prior to surgery and continued for 1 month (Imazio 2014b).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Patients &lt;70 kg: 0.5 mg once daily initiated 48 to 72 hours prior to surgery and continued for 1 month (Imazio 2014b).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment for concomitant therapy with CYP3A4 or P-glycoprotein (P-gp) inhibitors: </b> <b>Note:</b> Colcrys labeling recommends dosage adjustments in patients receiving CYP3A4 or P-gp inhibitors up to 14 days prior to initiation of colchicine. Treatment of gout flare with colchicine is not recommended in patients receiving prophylactic colchicine and CYP3A4 inhibitors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Coadministration of <b>strong</b> CYP3A4 inhibitor (eg, atazanavir, clarithromycin, darunavir/ritonavir, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, tipranavir/ritonavir):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">FMF: Maximum dose: 0.6 mg daily (0.3 mg twice daily)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gout prophylaxis:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Tablet: (eg, Colcrys):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">If original dose is 0.6 mg twice daily, adjust dose to 0.3 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">If original dose is 0.6 mg once daily, adjust dose to 0.3 mg every other day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Capsule (eg, Mitigare): Avoid concomitant use; if coadministration is necessary, reduce daily dosage or dose frequency and monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gout flare treatment: Initial: 0.6 mg, followed in 1 hour by a single dose of 0.3 mg; do not repeat for at least 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Coadministration of <b>moderate</b> CYP3A4 inhibitor (eg, aprepitant, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, verapamil):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">FMF: Maximum dose: 1.2 mg daily (0.6 mg twice daily)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gout prophylaxis:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Tablet (eg, Colcrys):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">If original dose is 0.6 mg twice daily, adjust dose to 0.3 mg twice daily <b>or</b> 0.6 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">If original dose is 0.6 mg once daily, adjust dose to 0.3 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Capsule (eg, Mitigare): Avoid concomitant use; if coadministration is necessary, reduce daily dosage or dose frequency and monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gout flare treatment: 1.2 mg as a single dose; do not repeat for at least 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Coadministration of P-gp inhibitor (eg, cyclosporine, ranolazine):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">FMF: Maximum dose: 0.6 mg daily (0.3 mg twice daily)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gout prophylaxis:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Tablet (eg, Colcrys):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">If original dose is 0.6 mg twice daily, adjust dose to 0.3 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">If original dose is 0.6 mg once daily, adjust dose to 0.3 mg every other day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Capsule (eg, Mitigare): Avoid concomitant use; if coadministration is necessary, reduce daily dosage or dose frequency and monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Gout flare treatment: Initial: 0.6 mg as a single dose; do not repeat for at least 3 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154325\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=colchicine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Colchicine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Familial Mediterranean fever (FMF):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet (eg, Colcrys) only:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 4 to 6 years: 0.3 to 1.8 mg daily in 1 to 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 6 to 12 years: 0.9 to 1.8 mg daily in 1 to 2 divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &gt;12 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gout prophylaxis/treatment:</b> Oral: Adolescents &gt;16 years: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154307\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Use caution; reduce prophylactic daily dose by 50% in individuals &gt;70 years (Terkeltaub 2009)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154308\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Concurrent use of colchicine and P-gp or strong CYP3A4 inhibitors is <b>contraindicated</b> in renal impairment. Fatal toxicity has been reported. Use of colchicine to treat gout flares is not recommended in patients with renal impairment receiving prophylactic colchicine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>FMF:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30 to 80 mL/minute: Monitor closely for adverse effects; dose reduction may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;30 mL/minute: Initial dose: 0.3 mg daily; use caution if dose titrated; monitor for adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dialysis: 0.3 mg as a single dose; use caution if dose titrated; dosing can be increased with close monitoring; monitor for adverse effects. Not removed by dialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Gout prophylaxis:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30 to 80 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Tablet (eg, Colcrys): Dosage adjustment not required; monitor closely for adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Capsule (eg, Mitigare): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;30 mL/minute:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Tablet (eg, Colcrys): Initial dose: 0.3 mg daily; use caution if dose titrated; monitor for adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Capsule (eg, Mitigare): There is no specific dosage adjustment provided in the manufacturer&rsquo;s labeling; dosage reduction or alternative therapy should be considered</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dialysis:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Tablet (eg, Colcrys): 0.3 mg twice weekly; monitor closely for adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Capsule (eg, Mitigare): There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal impairment with concomitant hepatic impairment: Capsule (eg, Mitigare): Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Gout flare treatment:</i> Tablet (eg, Colcrys): <b>Note:</b> Treatment of gout flares is not recommended in patients with renal impairment who are receiving colchicine for prophylaxis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30 to 80 mL/minute: Dosage adjustment not required; monitor closely for adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;30 mL/minute: Dosage reduction not required but may be considered; treatment course should not be repeated more frequently than every 14 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dialysis: 0.6 mg as a single dose; treatment course should not be repeated more frequently than every 14 days. Not removed by dialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Hemodialysis: Not dialyzable (0% to 5%); avoid chronic use of colchicine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154309\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Concurrent use of colchicine and P-glycoprotein or strong CYP3A4 inhibitors is <b>contraindicated</b> in hepatic impairment. Fatal toxicity has been reported. Treatment of gout flare with colchicine is not recommended in patients with hepatic impairment receiving prophylactic colchicine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>FMF:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate impairment: Use caution; monitor closely for adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment: There is no specific dosage adjustment provided in the manufacturer's labeling; dosage adjustment should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Gout prophylaxis:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate impairment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Tablet (eg, Colcrys): Dosage adjustment not required; monitor closely for adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Capsule (eg, Mitigare): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment: Tablet (eg, Colcrys) and Capsule (eg, Mitigare): There is no specific dosage adjustment provided in the manufacturer&rsquo;s labeling; dosage adjustment should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic impairment with concomitant renal impairment: Capsule (eg, Mitigare): Use is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Gout flare treatment:</i> <b>Note:</b> Treatment of gout flares is not recommended in patients with hepatic impairment who are receiving colchicine for prophylaxis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate impairment: Dosage adjustment not required; monitor closely for adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment: Dosage reduction not required but may be considered; treatment course should not be repeated more frequently than every 14 days.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154279\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mitigare: 0.6 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.6 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Colcrys: 0.6 mg [scored; contains fd&amp;c blue #2 (indigotine), fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.6 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154263\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8097684\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Colcrys:<a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022352s022lbl.pdf#page=24&amp;token=Y8XLqls8DA4CCB6ceSXpIei6XWhkpfA01eNqfOfVVV9WexeF5p9sIfiC/qWA+ryE+UCh5jFpI9ErmbfzshRcti0EYVmeemrv4TAm8d1K5V5T3RiqybbCbb6AvDwVcVaC&amp;TOPIC_ID=7483\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022352s022lbl.pdf#page=24</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Mitigare:<a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM417495.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/8bxp4YrxUVJFUAWh6274giuIJcKlHDBxiC41k8IE7QUA==&amp;TOPIC_ID=7483\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM417495.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154282\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Administer orally with water and maintain adequate fluid intake. May be administered without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49104450\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154281\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Familial Mediterranean fever (tablet [eg, Colcrys] only):</b> Treatment of familial Mediterranean fever in adults and children 4 years and older.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gout flares:</b> Prophylaxis and the treatment of acute gout flares when taken at the first sign of a flare. <b>Note:</b> Mitigare is only approved for prophylaxis of gout flares.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25572577\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Beh&ccedil;et syndrome; Pericarditis, acute (adults); Pericarditis, recurrent (adults); Postpericardiotomy syndrome (prevention)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154346\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Colchicine may be confused with Cortrosyn</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154270\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Gastrointestinal: Gastrointestinal disease (26% to 77%), diarrhea (23% to 77%), vomiting (17%), nausea (4% to 17%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Fatigue (1% to 4%), headache (1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Gout (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal cramps, abdominal pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pharyngolaryngeal pain (2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Alopecia, aplastic anemia, azoospermia, bone marrow depression, dermatitis, disseminated intravascular coagulation, dysgeusia (Syed 2016), granulocytopenia, hepatotoxicity, hypersensitivity reaction, increased creatine phosphokinase, increased serum ALT, increased serum AST, lactose intolerance, leukopenia, maculopapular rash, myalgia, myasthenia, myopathy, myotonia, neuropathy, oligospermia, pancytopenia, peripheral neuritis, purpura, rhabdomyolysis, skin rash, thrombocytopenia, toxic neuromuscular disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154285\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Concomitant use of a P-glycoprotein (P-gp) or strong CYP3A4 inhibitor in presence of renal or hepatic impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitigare: Patients with both renal and hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Canadian labeling: Additional contraindications (not in US labeling): Hypersensitivity to colchicine; serious gastrointestinal, hepatic, renal, and cardiac disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154267\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Blood dyscrasias: Myelosuppression (eg, thrombocytopenia, leukopenia, granulocytopenia, pancytopenia) and aplastic anemia have been reported in patients receiving therapeutic doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gastrointestinal symptoms: Dosage reduction is recommended in patients who develop gastrointestinal symptoms (anorexia, diarrhea, nausea, vomiting) related to drug therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neuromuscular toxicity: Myotoxicity (including rhabdomyolysis) has been reported in patients receiving therapeutic doses; patients with renal dysfunction and elderly patients are at increased risk. Concomitant use of cyclosporine, diltiazem, verapamil, fibrates, and statins may increase the risk of myopathy. Symptoms typically resolve within 1 week to several months of colchicine discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Clearance is decreased in hepatic impairment; monitor closely for adverse effects/toxicity. Dosage adjustments may be considered depending on degree of impairment or indication, and may be affected by the use of concurrent medication (CYP3A4 or P-gp inhibitors). Concurrent use of P-gp or strong CYP3A4 inhibitors is contraindicated in hepatic impairment. Fatal toxicity has been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Clearance is decreased in renal impairment; monitor closely for adverse effects/toxicity. Dosage adjustments may be required depending on degree of impairment or indication, and may be affected by the use of concurrent medication (CYP3A4 or P-gp inhibitors). Concurrent use of P-gp or strong CYP3A4 inhibitors is contraindicated in renal impairment. Fatal toxicity has been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in the elderly; literature suggests dosage adjustments should be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Colchicine is not an analgesic and should not be used to treat pain from other causes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Fatal overdose: Accidental and intentional fatal overdoses have been reported. Dosage associated with fatal toxicity is variable (eg, wide dosage range).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154332\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154272\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9293&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral Combination Products: May increase the serum concentration of Colchicine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Choline C 11: Colchicine may diminish the therapeutic effect of Choline C 11. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyanocobalamin: Colchicine may decrease the serum concentration of Cyanocobalamin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Colchicine. Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: May increase the serum concentration of Colchicine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fibric Acid Derivatives: May enhance the myopathic (rhabdomyolysis) effect of Colchicine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosamprenavir: May increase the serum concentration of Colchicine. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are receiving ritonavir-boosted fosamprenavir.  In those with normal renal and hepatic function, reduce colchicine dose as directed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May increase the serum concentration of Colchicine.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HMG-CoA Reductase Inhibitors (Statins): Colchicine may enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Fluoride (with ADE): Colchicine may decrease the serum concentration of Multivitamins/Fluoride (with ADE). Specifically, colchicine may decrease absorption of cyanocobalamin (vitamin B12). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): Colchicine may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, colchicine may decrease the serum concentration of Cyanocobalamin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with AE, No Iron): Colchicine may decrease the serum concentration of Multivitamins/Minerals (with AE, No Iron). Specifically, colchicine may decrease absorption of cyanocobalamin (vitamin B12). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased. Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): May increase the serum concentration of Colchicine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of Colchicine. Management: Colchicine should not be used with telaprevir in patients with impaired renal or hepatic function.  In those with normal renal and hepatic function, reduced colchicine doses (as directed) are required if used with telaprevir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May increase the serum concentration of Colchicine. Management: Colchicine should not be used with tipranavir in patients with impaired renal or hepatic function.  In those with normal renal and hepatic function, reduced colchicine doses (as directed) are required if used with tipranavir.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154299\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Grapefruit juice may increase colchicine serum concentrations. Management: Administer orally with water and maintain adequate fluid intake. Dose adjustment may be required based on indication if ingesting grapefruit juice. Avoid grapefruit juice with hepatic or renal impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154275\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10923644\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Colchicine crosses the human placenta. Use during pregnancy in the treatment of familial Mediterranean fever has not shown an increase in miscarriage, stillbirth, or teratogenic effects (limited data).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10923645\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Colchicine enters breast milk; exclusively breast-fed infants are expected to receive &lt;10% of the weight-adjusted maternal dose (limited data). The manufacturer recommends that caution be used if administered to a nursing woman. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154288\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May be taken without regard to meals. May need to supplement with vitamin B<sub>12</sub>. Avoid grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154277\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC, renal and hepatic function tests</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50782912\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Uric acid, serum:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Uric Acid Normal Values</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <col></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th>\n            <p style=\"text-indent:0em;text-align:center;\">Age</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Normal Serum Concentration</p></th></tr></thead>\n      <tbody>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">1 to 3 years</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1.8 to 5 mg/dL</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">4 to 6 years</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.2 to 4.7 mg/dL</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">7 to 9 years</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2 to 5 mg/dL</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Males 10 to 11 years</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.3 to 5.4 mg/dL</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Females 10 to 11 years</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3 to 4.7 mg/dL</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Males 12 to 13 years</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.7 to 6.7 mg/dL</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Males 14 to 15 years</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2.4 to 7.8 mg/dL</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Females 12 to 15 years</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3 to 5.8 mg/dL</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Males 16 to 19 years</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">4 to 8.6 mg/dL</p></td></tr>\n        <tr>\n          <td>\n            <p style=\"text-indent:0em;\">Females 16 to 19 years</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">3 to 5.9 mg/dL</p></td></tr></tbody></table>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Normal values:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Males: 3.4 to 7 mg/dL or slightly more</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Females: 2.4 to 6 mg/dL or slightly more</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Goal in gout (with urate-lowering therapy): &lt;6 mg/dL; &lt;5 mg/dL in patients with severe gout (eg, tophi, frequent attacks, chronic arthropathy) (ACR [Khanna 2012]; EULAR [Richette 2017]). Levels &lt;3 mg/dL are not recommended long term (EULAR [Richette 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154266\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Disrupts cytoskeletal functions by inhibiting &beta;-tubulin polymerization into microtubules, preventing activation, degranulation, and migration of neutrophils associated with mediating some gout symptoms. In familial Mediterranean fever, may interfere with intracellular assembly of the inflammasome complex present in neutrophils and monocytes that mediate activation of interleukin-1&beta;.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154284\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Oral: Pain relief: ~18 to 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Concentrates in leukocytes, kidney, spleen, and liver; does not distribute in heart, skeletal muscle, and brain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">V<sub>d</sub>: 5 to 8 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~39%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via CYP3A4; 3 metabolites (2 primary, 1 minor)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: ~45%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 27 to 31 hours (multiple oral doses; young, healthy volunteers)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral: 0.5 to 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (40% to 65% as unchanged drug); enterohepatic recirculation and biliary excretion also possible</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154287\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Colchicine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.6 mg (100): $653.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Mitigare Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.6 mg (100): $718.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Colchicine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.6 mg (100): $673.63</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Colcrys Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.6 mg (30): $244.01</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154289\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Artrichine (EC);</li>\n      <li>Calchicine Houde (PY);</li>\n      <li>Cholchicin &rdquo;Agepha&rdquo; (AT);</li>\n      <li>Cochic (TH);</li>\n      <li>Cocine (TW);</li>\n      <li>Colchicin Agepha (AT);</li>\n      <li>Colchicina Lirca (IT);</li>\n      <li>Colchicina Phoenix (AR);</li>\n      <li>Colchicine (IL);</li>\n      <li>Colchicine capsules (NL);</li>\n      <li>Colchicine Houde (AR, BE, FR, LU, PT);</li>\n      <li>Colchicum-Dispert (BG, DE, HU, PL, TR);</li>\n      <li>Colchifar (VN);</li>\n      <li>Colchily (TH);</li>\n      <li>Colchimedio (CO, CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Colchin (KR);</li>\n      <li>Colchiquim (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Colchis (BR);</li>\n      <li>Colchisol (PE);</li>\n      <li>Colchysat Burger (DE);</li>\n      <li>Colcine (TH);</li>\n      <li>Colcitex (SG);</li>\n      <li>Colgout (AU, HK, NZ);</li>\n      <li>Colmediten (KW, QA, SA);</li>\n      <li>Coluric (BD);</li>\n      <li>Conicine (TW);</li>\n      <li>Cryscol (BD);</li>\n      <li>Gotine (QA, SA);</li>\n      <li>Goutcolcin (VN);</li>\n      <li>Goutic (TH);</li>\n      <li>Goutichine (TH);</li>\n      <li>Goutnil (IN, LK, PH);</li>\n      <li>Kolchin (BD);</li>\n      <li>Kolhikum Dyspert (UA);</li>\n      <li>Kolkisin (NO);</li>\n      <li>L-Cisin (ID);</li>\n      <li>Lengout (AU);</li>\n      <li>Lennon-Colchicine (ZA);</li>\n      <li>Oripicin (VN);</li>\n      <li>Prochic (TH);</li>\n      <li>Recolfar (ID);</li>\n      <li>Sixol (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Tolchicine (TH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Adler Y, Charron P, Imazio M, et al. 2015 ESC guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS) [published online ahead of print August 29, 2015]. <i>Eur Heart J</i>. 2015.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-drug-information/abstract-text/26320112/pubmed\" target=\"_blank\" id=\"26320112\">26320112</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aktulga E, Alta&ccedil; M, M&uuml;ft&uuml;oglu A, et al. A double blind study of colchicine in Beh&ccedil;et's disease. <i>Haematologica</i>. 1980;65(3):399-402.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-drug-information/abstract-text/6778795/pubmed\" target=\"_blank\" id=\"6778795\">6778795</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Borstad GC, Bryant LR, Abel MP, et al, &ldquo;Colchicine for Prophylaxis of Acute Flares When Initiating Allopurinol for Chronic Gouty Arthritis,&rdquo; <i>J Rheumatol</i>, 2004, 31(12):2429-32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-drug-information/abstract-text/15570646/pubmed\" target=\"_blank\" id=\"15570646\">15570646</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC), &ldquo;Deaths From Intravenous Colchicine Resulting From a Pharmacy Compounding Error - Oregon and Washington, 2007,&rdquo; <i>MMWR Morb Mortal Wkly Rep</i>, 2007, 56(40):1050-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-drug-information/abstract-text/17932481/pubmed\" target=\"_blank\" id=\"17932481\">17932481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Colcrys (colchicine) [prescribing information]. Deerfield, IL: Takeda; December 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Emmerson BT, &ldquo;The Management of Gout,&rdquo; <i>N Engl J Med</i>, 1996, 334(7):445-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-drug-information/abstract-text/8552148/pubmed\" target=\"_blank\" id=\"8552148\">8552148</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. <i>Lancet</i>. 2014a;383(9936):2232-2237. doi: 10.1016/S0140-6736(13)62709-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-drug-information/abstract-text/24694983/pubmed\" target=\"_blank\" id=\"24694983\">24694983</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. <i>Circulation</i>. 2005a;112(13):2012-2016.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-drug-information/abstract-text/16186437/pubmed\" target=\"_blank\" id=\"16186437\">16186437</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Imazio M, Bobbio M, Cecchi E, et al. Colchicine as first-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. <i>Arch Intern Med</i>. 2005b;165(17):198719-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-drug-information/abstract-text/16186468/pubmed\" target=\"_blank\" id=\"16186468\">16186468</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Imazio M, Brucato A, Cemin R, et al; CORP (COlchicine for Recurrent Pericarditis) Investigators. Colchicine for recurrent pericarditis (CORP): a randomized trial. <i>Ann Intern Med</i>. 2011;155(7):409-414.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-drug-information/abstract-text/21873705/pubmed\" target=\"_blank\" id=\"21873705\">21873705</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Imazio M, Brucato A, Cemin R, et al; ICAP Investigators. A randomized trial of colchicine for acute pericarditis. <i>N Engl J Med</i>. 2013;369(16):1522-1528.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-drug-information/abstract-text/23992557/pubmed\" target=\"_blank\" id=\"23992557\">23992557</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Imazio M, Brucato A, Ferrazzi P, et al; COPPS-2 Investigators. Colchicine for prevention of postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical trial. <i>JAMA</i>. 2014b;312(10):1016-1023.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-drug-information/abstract-text/25172965/pubmed\" target=\"_blank\" id=\"25172965\">25172965</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Imazio M, Trinchero R, Brucato A, et al; COPPS Investigators. COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial. <i>Eur Heart J</i>. 2010a;31(22):2749-2754.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-drug-information/abstract-text/20805112/pubmed\" target=\"_blank\" id=\"20805112\">20805112</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Imazio M, Spodick DH, Brucato A, Trinchero R, Adler Y. Controversial issues in the management of pericardial diseases. <i>Circulation</i>. 2010b;121(7):916-928.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-drug-information/abstract-text/20177006/pubmed\" target=\"_blank\" id=\"20177006\">20177006</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kallinich T, Haffner D, Niehues T, et al, &ldquo;Colchicine Use in Children and Adolescents With Familial Mediterranean Fever: Literature Review and Consensus Statement,&rdquo; <i>Pediatrics</i>, 2007, 119(2):e474-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-drug-information/abstract-text/17242135/pubmed\" target=\"_blank\" id=\"17242135\">17242135</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khanna D, Khanna PP, Fitzgerald JD, et al; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2012;64(10):1447-1461.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-drug-information/abstract-text/23024029/pubmed\" target=\"_blank\" id=\"23024029\">23024029</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levy M, Spino M, and Read SE, &ldquo;Colchicine: A State-of-the-Art Review,&rdquo; <i>Pharmacotherapy</i>, 1991, 11(3):196-211.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-drug-information/abstract-text/1862011/pubmed\" target=\"_blank\" id=\"1862011\">1862011</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Majeed HA, Carroll JE, Khuffash FA, et al, &ldquo;Long-Term Colchicine Prophylaxis in Children With Familial Mediterranean Fever (Recurrent Hereditary Polyserositis),&rdquo; <i>J Pediatr</i>, 1990, 116(6):997-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-drug-information/abstract-text/2112191/pubmed\" target=\"_blank\" id=\"2112191\">2112191</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Majeed HA, Rawashdeh M, el-Shanti H, et al, &ldquo;Familial Mediterranean Fever in Children: The Expanded Clinical Profile,&rdquo; 1999, <i>QJM</i>, 92(6):309-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-drug-information/abstract-text/10616706/pubmed\" target=\"_blank\" id=\"10616706\">10616706</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Beh&ccedil;et's disease. <i>Lancet</i>. 1989;1(8647):1093-1096.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-drug-information/abstract-text/2566048/pubmed\" target=\"_blank\" id=\"2566048\">2566048</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mitigare (colchicine) [prescribing information]. Memphis, TN: Hikma Americas; November 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Gara PT, Kushner FG, Ascheim DD, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;127(4):e362-e425. doi: 10.1161/CIR.0b013e3182742cf6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-drug-information/abstract-text/23247304/pubmed\" target=\"_blank\" id=\"23247304\">23247304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    pms-Colchicine [product monograph]. Montreal, Quebec, Canada: Pharmascience Inc; February 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. <i>Ann Rheum Dis</i>. 2017;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-drug-information/abstract-text/27457514/pubmed\" target=\"_blank\" id=\"27457514\">27457514</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26899755\"></a>Syed Q, Hendler KT, Koncilja K. The impact of aging and medical status on dysgeusia. <i>Am J Med</i>. 2016;129(7):753.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-drug-information/abstract-text/26899755/pubmed\" target=\"_blank\" id=\"26899755\">26899755</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Terkeltaub RA, &ldquo;Colchicine Update: 2008,&rdquo; <i>Semin Arthritis Rheum</i>, 2009, 38(6):411-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-drug-information/abstract-text/18973929/pubmed\" target=\"_blank\" id=\"18973929\">18973929</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Terkeltaub RA, &ldquo;Gout,&rdquo; <i>N Engl J Med</i>, 2003, 349(17):1647-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-drug-information/abstract-text/14573737/pubmed\" target=\"_blank\" id=\"14573737\">14573737</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wallace SL, Singer JZ, Duncan GJ, et al, &ldquo;Renal Function Predicts Colchicine Toxicity: Guidelines for the Prophylactic Use of Colchicine in Gout,&rdquo; <i>J Rheumatol</i>, 1991, 18(2):264-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-drug-information/abstract-text/2023222/pubmed\" target=\"_blank\" id=\"2023222\">2023222</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yurdakul S, Mat C, T&uuml;z&uuml;n Y, et al. A double-blind trial of colchicine in Beh&ccedil;et's syndrome. <i>Arthritis Rheum</i>. 2001;44(11):2686-2692.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-drug-information/abstract-text/11710724/pubmed\" target=\"_blank\" id=\"11710724\">11710724</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zhang W, Doherty M, Bardin T, et al; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).<i> Ann Rheum Dis</i>. 2006;65(10):1312-1324.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/colchicine-drug-information/abstract-text/16707532/pubmed\" target=\"_blank\" id=\"16707532\">16707532</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9293 Version 174.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8108144\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F13869718\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F154338\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F154306\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F154325\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F154307\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F154308\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F154309\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F154279\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F154263\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F8097684\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F154282\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49104450\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F154281\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25572577\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F154346\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F154270\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F154285\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F154267\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F154332\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F154272\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F154299\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F154275\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F10923644\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F10923645\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F154288\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F154277\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F50782912\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F154266\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F154284\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F154287\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F154289\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9293|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=colchicine-patient-drug-information\" class=\"drug drug_patient\">Colchicine: Patient drug information</a></li><li><a href=\"topic.htm?path=colchicine-pediatric-drug-information\" class=\"drug drug_pediatric\">Colchicine: Pediatric drug information</a></li></ul></div></div>","javascript":null}